Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Depreciation & Amortization - Total: 2016-2024

Historic Depreciation & Amortization - Total for Vanda Pharmaceuticals (VNDA) over the last 9 years, with Dec 2024 value amounting to $900,000.

  • Vanda Pharmaceuticals' Depreciation & Amortization - Total rose 39.35% to $301,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 25.86%. This contributed to the annual value of $900,000 for FY2024, which is 2.17% down from last year.
  • According to the latest figures from FY2024, Vanda Pharmaceuticals' Depreciation & Amortization - Total is $900,000, which was down 2.17% from $920,000 recorded in FY2023.
  • Vanda Pharmaceuticals' 5-year Depreciation & Amortization - Total high stood at $1.4 million for FY2020, and its period low was $900,000 during FY2024.
  • In the last 3 years, Vanda Pharmaceuticals' Depreciation & Amortization - Total had a median value of $920,000 in 2023 and averaged $1.0 million.
  • Data for Vanda Pharmaceuticals' Depreciation & Amortization - Total shows a maximum YoY dropped of 24.40% (in 2023) over the last 5 years.
  • Vanda Pharmaceuticals' Depreciation & Amortization - Total (Yearly) stood at $1.4 million in 2020, then remained steady at $1.4 million in 2021, then dropped by 13.07% to $1.2 million in 2022, then declined by 24.40% to $920,000 in 2023, then decreased by 2.17% to $900,000 in 2024.